# A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

> **NCT01928329** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 79 (actual)

## Conditions studied

- Type I Diabetes

## Interventions

- **DRUG:** Exenatide (Bydureon®)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01928329
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2018-06
- **Final completion:** 2019-08
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2020-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01928329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01928329, "A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01928329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*